Efficacy and Safety of Ranolazine in Patients With Chronic Stable Angina

References

• . Go AS, Mozaffarian D, Roger VL, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245
   PubMed Web of Science ®Google Scholar
• . Fox K, Garcia MA, Ardissino D, ; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341–1381
   PubMed Web of Science ®Google Scholar
• . Fihn SD, Gardin JM, Abrams J, ; American College of Cardiology Foundation/American Heart Association Task Force. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354–e471
   PubMed Web of Science ®Google Scholar
• . Silverman ME. William Heberden and Some Account of a Disorder of the Breast. Clin Cardiol. 1987;10(3):211–213
   PubMedGoogle Scholar
• . Cannon CP, Brindis RG, Chaitman BR, ; American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards; American College of Emergency Physicians; Emergency Nurses Association; National Association of Emergency Medical Technicians; National Association of EMS Physicians; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Cardiovascular Patient Care; Society of Thoracic Surgeons. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013;127(9):1052–1089
   PubMedGoogle Scholar
• . Hemingway H, Langenberg C, Damant J, Frost C, Pyörälä K, Barrett-Connor E. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation. 2008;117(12): 1526–1536
   PubMedGoogle Scholar
• . Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. Am. Heart J. 2000;139(3):371–377
   PubMedGoogle Scholar
• . Ranexa extended-release tablets [prescribing information]. Foster City CA: Gilead Sciences, Inc.;2011
   Google Scholar
• . Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007;49(10):1027–1034
   PubMed Web of Science ®Google Scholar
• . Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, ; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775–1783
   PubMed Web of Science ®Google Scholar
• . Chaitman BR, Pepine CJ, Parker JO, ; Combination Assessment of Ranolanize in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–316
   PubMed Web of Science ®Google Scholar
• . Chaitman BR, Skettino SL, Parker JO, ; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–1382
   PubMed Web of Science ®Google Scholar
• . Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–575
   PubMed Web of Science ®Google Scholar
• . Scirica BM, Morrow DA Hod H, . Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647–1652
   PubMed Web of Science ®Google Scholar
• . Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95(3):311–316
   PubMed Web of Science ®Google Scholar
• . Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009;2(11):1301–1309
   PubMedGoogle Scholar
• . Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92( Suppl 4):iv6–iv14
   PubMed Web of Science ®Google Scholar
• . Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006;113(20):2462–2472
   PubMed Web of Science ®Google Scholar
• . Antzelevitch C, Belardinelli L, Zygmunt AC, . Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110(8):904–910
   PubMed Web of Science ®Google Scholar
• . Morrow DA, Scirica BM, Chaitman BR, ; MERLIN-TIMI 36 Investigators. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032–2039
   PubMed Web of Science ®Google Scholar
• . Kosiborod M, Arnold SV, Spertus JA, . Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038–2045
   PubMed Web of Science ®Google Scholar
• . Kloner RA, Dow JS, Bhandari A. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. J Cardiovasc Pharmacol. 2011;16(2):192–196
   Google Scholar
• . Kloner RA, Dow JS, Bhandari A. The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel. Cardiovasc Ther. 2011;29(4):e36–e41
   Google Scholar
• . Dhalla AK, Wang WQ, Dow J, . Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009;297(5):H1923–H1929
   Google Scholar
• . Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012;110(5):673–677
   PubMedGoogle Scholar
• . Simopoulos V, Tagarakis GI, Daskalopoulou SS, . Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery [published online ahead of print February 25, 2013]. Angiology. doi:10.1177/0003319713477911
   Google Scholar
• . Chaitman BR. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. J Cardiovasc Pharmacol Ther. 2004;9( Suppl 1):S47–S64
   PubMedGoogle Scholar
• . Arnold SV, Chan PS, Jones PG, . Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients: Health Status (TRIUMPH): design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes. 2011;4(4):467–476
   PubMed Web of Science ®Google Scholar
• . Arnold S, Spertus J, Lipska K, . Association of diabetes mellitus with post-myocardial infarction angina: analysis of the TRIUMPH prospective cohort study [abstract]. J Am Coll Cardiol. 2013;61( 10 suppl):E1561
   Google Scholar
• . Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27(1):42–48
   PubMed Web of Science ®Google Scholar
• . Jerling M, Huan BL, Leung K, Chu N, Abdallah H, Hussein Z. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45(4):422–433
   PubMed Web of Science ®Google Scholar